Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00667121 · ClinicalTrials.gov registry record
Tamoxifen in Women With Breast Cancer and in Women at High-Risk of Breast Cancer Who Are Receiving Venlafaxine, Citalopram, Escitalopram, Gabapentin, or Sertraline
A clinical trial, sponsored by Mayo Clinic.
- Completed
- Registry status
- 88
- Enrollment target
NCT00667121: Completed study, sponsored by Mayo Clinic.
NCT00667121 is a clinical trial that has completed, run by Mayo Clinic. The registered enrollment target is 88 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00667121 has completed, sponsored by Mayo Clinic.
- COMPLETED
- Registry status
- 88 participants
- Enrollment target
Study Summary
RATIONALE: Studying samples of blood in the laboratory from patients receiving tamoxifen may help doctors learn more about the effects of other drugs on the level of tamoxifen in the blood. PURPOSE: This clinical trial is studying levels of tamoxifen in the blood of women with breast cancer and in women at high risk of breast cancer who are receiving tamoxifen together with venlafaxine, citalopram, escitalopram, gabapentin, or sertraline.
Interventions
- DRUG tamoxifen citrate
- DRUG gabapentin
- DRUG sertraline hydrochloride
- DRUG citalopram hydrobromide
- DRUG escitalopram oxalate
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 88 participants |
| Start Date | 2011-03-16 |
| Est. Completion | 2014-05-27 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00667121
The ClinicalTrials.gov registry entry for NCT00667121 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 88 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Mayo Clinic, which has 2,844 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which tamoxifen citrate is the first listed.
NCT00667121 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00667121 about?
NCT00667121 is a clinical study titled "Tamoxifen in Women With Breast Cancer and in Women at High-Risk of Breast Cancer Who Are Receiving Venlafaxine, Citalopram, Escitalopram, Gabapentin, or Sertraline". RATIONALE: Studying samples of blood in the laboratory from patients receiving tamoxifen may help doctors learn more about the effects of other drugs on the level of tamoxifen in the blood. PURPOSE: This clinical trial is studying levels of tamoxifen in the blood of women with breast cancer and in ...
What is the current status of trial NCT00667121?
This trial is currently completed. The enrollment target is 88 participants. The study started on 2011-03-16. Estimated completion is 2014-05-27.
What interventions are being tested in trial NCT00667121?
The interventions under investigation include: tamoxifen citrate (DRUG), gabapentin (DRUG), sertraline hydrochloride (DRUG), citalopram hydrobromide (DRUG), escitalopram oxalate (DRUG).
Who is sponsoring clinical trial NCT00667121?
This trial is sponsored by Mayo Clinic, which has 2,844 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.